Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Regains Nasdaq Listing Compliance

NEW YORK (GenomeWeb News) – CombiMatrix today said that it has regained compliance with a Nasdaq listing requirement calling for at least $2.5 million in stockholders' equity.

The Director of Listing Qualifications informed the Irvine, Calif.-based firm of its compliance in a letter dated Aug. 20, saying that based on CombiMatrix's Form 10-Q for the second quarter, which indicated that it had stockholders' equity of $5.7 million, the Nasdaq staff determined that the company was in compliance and "the matter is now closed."

CombiMatrix was warned by Nasdaq of its non-compliance in March, and it originally gave the firm until April 25 to submit a plan to regain compliance. The plan was submitted, and in May Nasdaq extended the deadline under which CombiMatrix had to provide evidence that it was in compliance with the Nasdaq rule.

Earlier this month, the company reported a 15 percent jump in its second quarter revenues.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.